American patients

Afectado por Incidentes

Incidente 1723 Reportes
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

2020-07-01

NarxCare's overdose risk algorithm, lacking peer-reviewed validation, uses sensitive data like doctor visits, prescriptions, and possibly genetic information, leading to significant biases against women and Black patients. Factors like sexual abuse and criminal records exacerbate stigmas and disparities, often resulting in unjust denial of necessary pain medication. The newly approved AvertD genetic test shares similar issues, further complicating and potentially harming medical treatment decisions.

Related Entities

Appriss

Incidentes involucrados como desarrollador e implementador

Incidente 172
3 Reportes
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

NarxCare

Incidents involved as Deployer

Incidente 172
3 Reportes
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

AvertD

Incidents involved as Deployer

Incidente 172
3 Reportes
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

American physicians

Afectado por Incidentes

Incidente 172
3 Reportes
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

American pharmacists

Afectado por Incidentes

Incidente 172
3 Reportes
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

American patients of minority groups

Afectado por Incidentes

Incidente 172
3 Reportes
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias